May 28, 2017 2:52 AM ET

Biotechnology

Company Overview of Stellar Biotechnologies, Inc.

Company Overview

Stellar Biotechnologies, Inc., a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein primarily in Europe, the United States, and Asia. It provides KLH, an immune-stimulating molecule used as an active pharmaceutical ingredient in various immunotherapies; and as an injectable product to assess immune response. The company offers its KLH protein under the Stellar KLH brand. Its products include Stellar KLH protein in various grades, formulations, and configurations for preclinical and clinical applications, as well as certain KLH-based in vitro diagnostic kits for preclinical use. The company...

332 East Scott Street

Port Hueneme, CA 93041

United States

23 Employees

Phone:

805-488-2800

Fax:

805-488-2889

Key Executives for Stellar Biotechnologies, Inc.

Chairman of the Board, Chief Executive Officer and President
Age: 66
Total Annual Compensation: $370.1K
Chief Financial Officer and Corporate Secretary
Age: 59
Total Annual Compensation: $243.8K
Compensation as of Fiscal Year 2016.

Stellar Biotechnologies, Inc. Key Developments

Stellar Biotechnologies, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended March 31, 2017

Stellar Biotechnologies, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended March 31, 2017. For the quarter, the company reported total revenues of $63,019 compared to $326,335 for the same period a year ago. The change in Revenue was due to a decrease in product sales volume. Loss from operations was $1,147,557 compared to $1,095,943 for the same period a year ago. Net loss was $1,103,677 or $0.11 per basic and diluted share compared to $861,010 or $0.10 per basic and diluted share for the same period a year ago. For the six months, the company reported total revenues of $204,875 compared to $814,495 for the same period a year ago. Loss from operations was $2,562,033 compared to $2,403,297 for the same period a year ago. Net loss was $2,589,349 or $0.26 per basic and diluted share compared to $2,490,813 or $0.30 per basic and diluted share for the same period a year ago. Net cash used in operating activities was $2,641,197 compared to $2,247,526 for the same period a year ago. Acquisition of property, plant and equipment was $126,876 compared to $263,242 for the same period a year ago.

Stellar Biotechnologies, Inc. and Matrivax Inc. Enters into Agreement for Technology Transfer and Purchase Agreement Related to Stellar's Proprietary Clostridium Difficile Technology

Stellar Biotechnologies, Inc. and Matrivax Inc. announced that the companies have entered into a technology transfer and purchase agreement related to Stellar's proprietary Clostridium difficile technology. Under the terms of the agreement, Stellar will transfer its proprietary rights and know-how of immunogens and vaccine technology for a life-threatening pathogenic bacteria known as Clostridium difficile. Stellar advanced this technology through exploratory preclinical studies completed under an exclusive license of the patented immunotherapy technology from the University of Guelph, Canada.

Stellar Biotechnologies Inks Multiyear KLH Supply Agreement with Amaran Biotechnology

Stellar Biotechnologies and Amaran Biotechnology have entered into an exclusive agreement where Stellar will supply KLH to Amaran Biotechnology.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Stellar Biotechnologies, Inc., please visit www.stellarbiotechnologies.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.